BridgeBio Pharma, Inc. — Director's Dealing 2020

Jun 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-06-08

Reporting Person: HENDERSON MICHAEL THOMAS (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-08	Common Stock	S	506	$30.00	Disposed	260393	Direct
2020-06-08	Common Stock	S	100	$30.0525	Disposed	260293	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019.